Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
$588M |
| 2 |
Apple
AAPL
|
$574M |
| 3 |
Illumina
ILMN
|
$398M |
| 4 |
argenx
ARGX
|
$306M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$250M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$600M |
| 2 |
AbbVie
ABBV
|
$323M |
| 3 |
Sherwin-Williams
SHW
|
$309M |
| 4 |
Atlassian
TEAM
|
$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Icon
ICLR
$13.7B
| $179M | 0.12% |
838,246
-148,318
| -15% | -$31.7M |
|
177
Schwab US Large- Cap ETF
SCHX
$59.3B
| $178M | 0.12% |
11,009,955
-613,938
| -5% | -$9.9M |
|
178
RB Global
RBA
$21.5B
| $176M | 0.12% |
3,128,099
-669,039
| -18% | -$37.7M |
|
179
Casey's General Stores
CASY
$18.5B
| $172M | 0.11% |
794,960
-11,913
| -1% | -$2.58M |
|
180
Oracle
ORCL
$626B
| $171M | 0.11% |
1,837,507
-469,351
| -20% | -$43.6M |
|
181
Keysight
KEYS
$28.7B
| $167M | 0.11% |
1,033,369
+974,157
| +1,645% | +$157M |
|
182
Visteon
VC
$3.42B
| $164M | 0.11% |
1,047,863
-437,341
| -29% | -$68.6M |
|
183
Constellium
CSTM
$1.95B
| $163M | 0.11% |
10,649,744
+242,568
| +2% | +$3.71M |
|
184
Regeneron Pharmaceuticals
REGN
$60.1B
| $162M | 0.11% |
197,071
-49,951
| -20% | -$41M |
|
185
Alight
ALIT
$2.02B
| $161M | 0.11% |
17,458,609
+4,752,133
| +37% | +$43.8M |
|
186
Axon Enterprise
AXON
$57.3B
| $159M | 0.1% |
707,671
-272,211
| -28% | -$61.2M |
|
187
Stellantis
STLA
$26.2B
| $159M | 0.1% |
8,762,554
+2,634,997
| +43% | +$47.8M |
|
188
Burlington
BURL
$19B
| $156M | 0.1% |
770,832
-501,616
| -39% | -$101M |
|
189
Apollo Global Management
APO
$77.1B
| $155M | 0.1% |
2,461,039
-1,090,672
| -31% | -$68.9M |
|
190
Walker & Dunlop
WD
$2.84B
| $155M | 0.1% |
2,034,574
+31,253
| +2% | +$2.38M |
|
191
PTC Therapeutics
PTCT
$4.61B
| $155M | 0.1% |
3,196,304
+1,169,162
| +58% | +$56.6M |
|
192
Euronet Worldwide
EEFT
$3.73B
| $154M | 0.1% |
1,376,643
-85,335
| -6% | -$9.55M |
|
193
Travere Therapeutics
TVTX
$1.89B
| $154M | 0.1% |
6,845,813
+1,754,528
| +34% | +$39.5M |
|
194
Chipotle Mexican Grill
CMG
$55.5B
| $152M | 0.1% |
4,462,150
+157,850
| +4% | +$5.39M |
|
195
Amicus Therapeutics
FOLD
$2.47B
| $151M | 0.1% |
13,610,435
-84,114
| -0.6% | -$933K |
|
196
Organon & Co
OGN
$2.52B
| $149M | 0.1% |
6,324,728
-5,695,846
| -47% | -$134M |
|
197
Yum China
YUMC
$16.4B
| $149M | 0.1% |
2,370,452
-187,901
| -7% | -$11.8M |
|
198
Xylem
XYL
$34.5B
| $147M | 0.1% |
1,402,244
+629,275
| +81% | +$65.9M |
|
199
Magnolia Oil & Gas
MGY
$4.56B
| $146M | 0.1% |
6,693,932
-583,409
| -8% | -$12.8M |
|
200
Pfizer
PFE
$140B
| $146M | 0.1% |
3,579,172
+54,860
| +2% | +$2.24M |
|